Clinical Trial

Patient-derived Organoids of Lung Cancer to Test Drug Response

Recruiting
View on ClinicalTrials.gov →
Summary
This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2019-06-06; most recent amendment 2024-05-31.
Trial Details
NCT Number NCT03979170
Lead Sponsor University Hospital, Geneva
Conditions Lung Cancer, Organoid
Enrollment 50 participants
Start Date 2019-04-01
Primary Completion 2026-12-30 (estimated)
Study Completion 2029-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-06-03